![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Guilford Publications Inc
ISSN: 1085-0295
Source: Child and Adolescent Psychopharmacology News, Vol.14, Iss.1, 2009-02, pp. : 6-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Black box warning added to US Dryvax label
Reactions Weekly, Vol. 1, Iss. 1029, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
New black box warning for nefazodone in the US
Inpharma, Vol. 1, Iss. 1321, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Black-box warning messages differ between FDA, lay media
Reactions Weekly, Vol. 1, Iss. 1282, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The US FDA `Black Box' Warning for Topical Calcineurin Inhibitors: An Ongoing Controversy
Drug Safety, Vol. 31, Iss. 3, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Rosiglitazone: FDA must provide more than black box warning
Reactions Weekly, Vol. 1, Iss. 1314, 2010-01 ,pp. :